Results 161 to 170 of about 1,275 (171)

Idursulfase: a poor risk-benefit balance in type II mucopolysaccharidosis.

Prescrire international, 2008
Weekly infusions of idursulfase have no tangible benefit in boys with type II mucopolysaccharidosis who already have respiratory involvement, while hypersensitivity reactions are frequent and sometimes serious. Idursulfase should only be given to infants if they are enrolled in clinical trials.
openaire   +1 more source

Idursulfase

Reactions Weekly, 2017
openaire   +1 more source

Elaprase (idursulfase)

PharmaDeals Review, 2006
openaire   +1 more source

Idursulfase withdrawal

Reactions Weekly, 2013
openaire   +1 more source

Efficacy, effectiveness, safety and simplified estimate of budgetary impact of idursulfase and idursulfase beta for mucopolysaccharidosis II

2019
Almeida, Paulo Henrique Ribeiro Fernandes, Lemos, Lívia Lovato Pires De, Junior, Augusto Afonso Guerra, Alvares, Juliana   +3 more
openaire   +1 more source

Biodistribution of idursulfase in cynomolgus monkeys after intrathecal-lumbar administration

Molecular Genetics and Metabolism, 2016
Jou-Ku Chung, Eilish Brown, Robert Crooker, Kathleen J. Palmieri, Thomas G. McCauley   +4 more
openaire   +1 more source

Idursulfase approved in Mexico.

Inpharma Weekly, 2008
openaire   +1 more source

Idursulfase approved in Brazil for MPS II.

Inpharma Weekly, 2008
openaire   +1 more source

Idursulfase

Reactions Weekly
openaire   +1 more source

Chlorphenamine/idursulfase/laronidase

Reactions Weekly
openaire   +1 more source